Icosavax is a Seattle-based biopharmaceutical company developing a vaccine candidate for respiratory syncytial virus and human metapneumovirus. The vaccine elicited a strong immune response against both viruses one month after vaccination in phase 2 trial.
Currently, there are no vaccines on the market for human metapneumovirus, and no combination vaccine for RSV, the drugmakers said.
The acquisition would put AstraZeneca in direct competition with GlaxoSmithKline and Pfizer, which both launched RSV vaccines in 2023.
The deal is expected to close in the first quarter of next year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
